Meeting | Virtual

Meeting Overview:

On September 29, 2026, the Food and Drug Administration’s, Center for Biologics Evaluation and Research, Office of Blood Research and Review is hosting a roundtable on strengthening the supply chain for the collection and manufacturing of Whole Blood and blood components for transfusion and further manufacturing, including Source Plasma.
The purpose of the roundtable is to identify supply chain challenges and potential solutions to prevent shortages of supplies and equipment used in blood manufacturing to help ensure a safe and adequate blood supply in the United States. During this one-day meeting, FDA and other key stakeholders, including representatives from the blood collection industry, supply chain manufacturers, and federal agencies in the Department of Health and Human Services will discuss current challenges and offer strategies to strengthen and build resilience in the supply chain for blood manufacturing.  
There will be three sessions focused on: (1) current challenges to supply chain disruptions involving blood manufacturing, (2) manufacturers’ perspectives on the root causes of supply chain disruptions and potential solutions, and (3) the role of federal agencies in strengthening and building resilience in the supply chain. For each session, there will be presentations from designated speakers, followed by a brief facilitated discussion. There will be an opportunity for public participation during an open public comment session.

Meeting Objectives:

• Describe the supply chain for blood manufacturing and identify what supplies and equipment are essential to manufacturing blood and blood components.
• Discuss current challenges and how blood collectors respond to shortages in the supply chain.
• Identify the root cause of shortages in the supply chain and propose solutions to prevent such shortages.
• Discuss the role of various federal agencies in strengthening the supply chain for blood manufacturing.

Meeting Logistics and Registration:

The virtual meeting is free and open to the public; however, registration is required.  Early registration is recommended.

• Registration: To register for the webinar, please visit the following link: https://events.gcc.teams.microsoft.com/event/OBRRroundtable2026
• Request to participate in open public comment session: Individuals interested in providing brief comments during the public comment session must indicate their interest during online registration. Requests to present must be received by 11:59 p.m. ET on Friday, September 4, 2026. Participation in the session and the time allotted for each speaker will be limited. You will be notified of your participation in the session by September 15, 2026.
• A recording and other relevant meeting materials will be posted online following the event.
• For questions regarding this event, please contact CBERPublicEvents@fda.hhs.gov.